Gilead (GILD) New Drug Filgotinib is Relatively Safe, But Black Box Still Likely - Baird
Tweet Send to a Friend
Baird analyst Brian Skorney reiterated a Neutral rating and $75 price target on Gilead Sciences (NASDAQ: GILD) citing earnings stabilization ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
